BTIG analyst Thomas Shrader has maintained their bullish stance on GANX stock, giving a Buy rating on November 13.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Thomas Shrader’s rating is based on several promising developments in Gain Therapeutics’ clinical trials and financial health. The company’s investigational drug, GT-02287, has shown potential in treating Parkinson’s disease by improving key clinical scores and demonstrating a disease-slowing effect. The drug was well tolerated with no significant adverse events, and a majority of participants opted to continue treatment, indicating positive patient reception.
Furthermore, the upcoming biomarker data is anticipated to provide further insights into the drug’s efficacy, particularly in clearing harmful deposits in lysosomes, which could be a significant breakthrough. Financially, the company maintains a stable cash position, and the valuation using a discounted cash flow analysis suggests potential growth. These factors combined contribute to Shrader’s Buy rating for Gain Therapeutics.
In another report released on November 13, Roth MKM also reiterated a Buy rating on the stock with a $6.00 price target.